Searchable abstracts of presentations at key conferences in endocrinology

ea0081p150 | Pituitary and Neuroendocrinology | ECE2022

Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind randomized placebo-controlled study

Atila Cihan , Gaisl Odile , Vogt Deborah , Werlen Laura , Szinnai Gabor , Christ-Crain Mirjam

Background: The differential diagnosis between central diabetes insipidus and primary polydipsia is challenging. To date, the most reliable approaches are copeptin measurement after hypertonic saline infusion or arginine, which is a known growth hormone secretagogue but has recently been shown also to stimulate the neurohypophysis. Similar to arginine, glucagon is also known to stimulate growth hormone release, but its effect on the neurohypophysis and in the differential diag...

ea0049ep889 | Neuroendocrinology | ECE2017

Empagliflozin increases urinary volume output in healthy volunteers with artificial SIADH – a placebo-controlled double blind crossover study

Refardt Julie , Winzeler Bettina , Meienberg Fabian , Vogt Deborah , Christ-Crain Mirjam

Introduction: The Syndrome of inappropriate antidiuresis (SIADH) is the predominant cause of hyponatremia and its therapy options are unsatisfying. SGLT2-inhibitors have become a valuable treatment option for type 2 diabetes by increasing glucose excretion in the urine with concomitant osmotic diuresis. We therefore hypothesized that SGLT2-inhibitors could be a novel treatment option for SIADH.Material and methods: We included 14 healthy volunteers in th...

ea0073aep467 | Pituitary and Neuroendocrinology | ECE2021

The GLP-1 receptor agonist dulaglutide reduces fluid intake in primary polydipsia: A randomised controlled trial

Winzeler Bettina , Sailer Clara , David Coynel , Zanchi Davide , Vogt Deborah , Urwyler Sandrine , Refardt Julie , Christ-Crain Mirjam

BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide-1 (GLP-1) reduces appetite and food intake. In experimental models, they also play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.<p class="abstext"...

ea0081p165 | Pituitary and Neuroendocrinology | ECE2022

Effects of the SGLT2-inhibitor empagliflozin in patients with chronic syndrome of inadequate antidiuresis (SIAD) - results of a double-blind, randomized, placebo-controlled, crossover trial

Refardt Julie , Imber Cornelia , Nobbenhuis Rianne , Clara Odilia Sailer , Haslbauer Aaron , Vogt Deborah , Berres Manfred , Winzeler Bettina , Bridenbaugh Stephanie , Mirjam Christ-Crain

Introduction: Hyponatremia is the most common electrolyte disorder and the syndrome of inappropriate antidiuresis (SIAD) is one of its main causes. However, treatment options for chronic SIAD-induced hyponatremia are inadequate. This is problematic because hyponatremia has been associated with neurocognitive deficits, although there is little data on its reversibility. We previously showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin is a promising s...

ea0090p69 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Effects of Glucagon-Like Peptide-1 Analogs on Sexual Desire: A randomized, double-blind, placebo-controlled crossover trial

Lengsfeld Sophia , Hasenbohler Flavia , Probst Leila , Baur Fabienne , Emara Yara , Bathelt Cemile , Werlen Laura , Vogt Deborah , Caviezel Brida , Vukajlovic Tanja , Christ-Crain Mirjam , Winzeler Bettina

Background: GLP-1 analogs are prescribed for diabetes and obesity due to their well-known insulinotropic, satiation-promoting and appetite-suppressant effects. Several studies also investigated the effects of GLP-1 analogs on reward to addictive drugs such as alcohol, nicotine and cocaine. Pre-clinical studies suggest that sexual desire, as another type of natural reward, could also be affected by GLP-1 analogs. Since sexuality is a very important aspect of human wellbeing and...

ea0063oc13.2 | Anterior and Posterior pituitary 2 | ECE2019

Empagliflozin increases sodium-levels in patients with the syndrome of inappropriate antidiuretic hormone secretion – a randomized, double-blind, placebo-controlled trial

Refardt Julie , Imber Cornelia , Sailer Clara O , Jeanloz Nica , Potasso Laura , Kutz Alexander , Widmer Andrea , Urwyler Sandrine , Ebrahimi Fahim , Vogt Deborah R , Winzeler Bettina , Christ-Crain Mirjam

Introduction: The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the predominant cause of hyponatremia but the available treatment options are unsatisfying and often of little efficiency. The selective sodium-glucose co-transporter 2 inhibitor empagliflozin promotes osmotic diuresis due to glucosuria and might be a novel treatment option for SIADH.Material and methods: From September 2016 through December 2018 we randomly assigned 88...

ea0063gp1 | Adrenal and Neuroendocrine - Tumour | ECE2019

68Ga-exendin-4 PET/CT detects insulinomas in patients with hypoglycemia in multiple endocrine neoplasia type 1

Antwi Kwadwo , Nicolas Guillaume , Fanis Melpomeni , Heye Tobias , Pattou Francois , Grossman Ashley , Chanson Philippe , Reubi Jean Claude , Perren Aurel , Gloor Beat , Vogt Deborah , Wild Damian , Christ Emanuel

Context: Surgical intervention is advised in patients with multiple endocrine neoplasia type-1 (MEN-1) with non-functioning pancreatic neuroendocrine tumors (PanNET) and a size ≥20 mm. However, functioning PanNET such as patients with endogenous hyperinsulinemic hypoglycemia (EHH) due to (one or multiple) insulinomas should be treated surgically independent of size. Reliable preoperative localization of insulinomas is critical for surgical strategy.<p class="abstext"...

ea0073oc4.1 | Oral Communications 4: Reproductive and Developmental Endocrinology | ECE2021

Effect of IL-1 receptor antagonism on hyperandrogenemia in women with polycystic ovary syndrome

Popovic Milica , Schiffer Lina , Taylor Angela E. , Arlt Wiebke , Vogt Deborah , De Geyter Christian , Sartorius Gideon , Donath Marc Y. , Christ-Crain Mirjam

BackgroundPolycystic Ovary Syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age. The main components are hyperandrogenemia and oligo-/amenorrhea. The pathophysiology of PCOS is not fully understood which is why no causal treatment options are available. A multitude of observational studies demonstrated elevated C-reactive protein (CRP) levels in patients with PCOS compared with weight-matched controls. CRP is a sensitive ...

ea0063oc13.1 | Anterior and Posterior pituitary 2 | ECE2019

Arginine-stimulated copeptin measurements - a new test for diabetes insipidus

Winzeler Bettina , Nigro-Cesana Nicole , Refardt Julie , Vogt Deborah R , Imber Cornelia , Morin Benedict , Popovic Milica , Steinmetz Michelle , Sailer Clara , Szinnai Gabor , Chifu Irina , Fassnacht Martin , Christ-Crain Mirjam

Background: The differential diagnosis of diabetes insipidus is challenging. The most reliable diagnostic approach is hypertonic saline-stimulated copeptin measurements. However, as this test is based on the induction of hypernatremia, it is associated with adverse effects and needs close sodium monitoring. We hypothesized that arginine-stimulated copeptin measurements provide an alternative, simple and safe diagnostic test for diabetes insipidus.Methods...

ea0081p76 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP – a randomised controlled study

Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Steinmetz Michelle , Sailer Clara , Coynel David , Vogt Deborah R , Hemkens Lars G. , Speich Benjamin , Kuhne Jill , Baur Fabienne , Lutz Linda , Bathelt Cemile , Zanchi Davide , Christ-Crain Mirjam , Winzeler Bettina

Background: Cigarette smoking is the leading preventable cause of premature death. Smoking cessation is one of the central goals in medicine, but despite dedicated programs, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight and seem to modulate addictive behavior. These GLP-1 properties are of major interest in the context of smoking cessation....